Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/bjh.19086
Keywords
acute myeloid leukaemia; children; haploidentical haematopoietic stem cell transplantation; high risk; minimal residual disease
Categories
Ask authors/readers for more resources
Data analysis of 200 children with high-risk acute myeloid leukaemia undergoing haploidentical haematopoietic stem cell transplantation showed a 4-year overall survival of 71.9%, event-free survival of 62.3% and cumulative incidence of relapse of 32.4%. Minimal residual disease positivity before transplantation was significantly associated with lower survival and higher risk of relapse. Haploidentical stem cell transplantation can be considered as a therapy option, and pre-transplantation minimal residual disease status significantly affects outcomes.
Data from 200 children with high-risk acute myeloid leukaemia who underwent their first haploidentical haematopoietic stem cell transplantation (haplo-HSCT) between 2015 and 2021 at our institution were analysed. The 4-year overall survival (OS), event-free survival (EFS) and cumulative incidence of relapse (CIR) were 71.9%, 62.3% and 32.4% respectively. The 100-day cumulative incidences of grade II-IV and III-IV acute graft-versus-host disease (aGVHD) were 41.1% and 9.5% respectively. The 4-year cumulative incidence of chronic GVHD (cGVHD) was 56.1%, and that of moderate-to-severe cGVHD was 27.3%. Minimal residual disease (MRD)-positive (MRD+) status pre-HSCT was significantly associated with lower survival and a higher risk of relapse. The 4-year OS, EFS and CIR differed significantly between patients with MRD+ pre-HSCT (n = 97; 63.4%, 51.4% and 41.0% respectively) and those with MRD-negative (MRD-) pre-HSCT (n = 103; 80.5%, 73.3% and 23.8% respectively). Multivariate analysis also revealed that acute megakaryoblastic leukaemia without Down syndrome (non-DS-AMKL) was associated with extremely poor outcomes (hazard ratios and 95% CIs for OS, EFS and CIR: 3.110 (1.430-6.763), 3.145 (1.628-6.074) and 3.250 (1.529-6.910) respectively; p-values were 0.004, 0.001 and 0.002 respectively). Thus, haplo-HSCT can be a therapy option for these patients, and MRD status pre-HSCT significantly affects the outcomes. As patients with non-DS-AMKL have extremely poor outcomes, even with haplo-HSCT, a combination of novel therapies is urgently needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available